Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_4
1
33%
Ph not_applicable
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Completed1
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

completed133%
withdrawn133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
completedphase_4

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

NCT02982187
withdrawnnot_applicable

Description of the Ability to Learn How to Handle Inhaler Devices in Asthma

NCT03175926

Clinical Trials (3)

Showing 3 of 3 trials
NCT03345407Phase 2

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Terminated
NCT02982187Phase 4

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

Completed
NCT03175926Not Applicable

Description of the Ability to Learn How to Handle Inhaler Devices in Asthma

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3